Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Appointed COO
Appointed director
BridgeBio Pharma, Inc. (BBIO) Create: Alert

All | News | Filings
Date FiledTypeDescription
07/19/2023 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
02/17/2021 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
01/26/2021 SC 13D/A Eidos Therapeutics, Inc. reports a 0% stake in BridgeBio Pharma, Inc.
01/26/2021 SC 13D/A BridgeBio Pharma, Inc. reports a 100% stake in Eidos Therapeutics, Inc.
10/06/2020 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
10/05/2020 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
06/01/2020 SC 13D/A KKR Genetic Disorder L.P. reports a 28.4% stake in BridgeBio Pharma Inc.
10/15/2019 SC 13D/A BridgeBio Pharma LLC reports a 65.6% stake in Eidos Therapeutics, Inc.
08/08/2019 SC 13D/A BridgeBio Pharma LLC reports a 66.6% stake in Eidos Therapeutics, Inc.

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy